{"id":688607,"date":"2010-03-11T09:37:35","date_gmt":"2010-03-11T14:37:35","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=67860"},"modified":"2010-03-11T09:37:35","modified_gmt":"2010-03-11T14:37:35","slug":"seattle-genetics-adds-patent-to-2025","status":"publish","type":"post","link":"https:\/\/mereja.com\/index\/688607","title":{"rendered":"Seattle Genetics Adds Patent to 2025"},"content":{"rendered":"\n
Biotech<\/a>, cancer<\/a>, Hodgkin’s disease<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Seattle Genetics, the developer of antibody treatments for cancer, said today<\/a> it has received a new patent which will extend its proprietary rights to its lead drug for Hodgkin’s disease until at least 2025. The U.S. patent covers technology for a linker that selectively unloads a potent toxin called auristatin on the target cell of interest. This is the technology Seattle Genetics uses in its lead “empowered antibody” program called brentuximab vedotin<\/a> (SGN-35), and which several of its partners use under licenses. Seattle Genetics expects to seek FDA approval of brentuximab vedotin to treat Hodgkin’s disease in the first half of 2011.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, cancer, Hodgkin’s disease Luke Timmerman wrote: Seattle Genetics, the developer of antibody treatments for cancer, said today it has received a new patent which will extend its proprietary rights to its lead drug for Hodgkin’s disease until at least 2025. The U.S. patent covers technology for a linker that selectively unloads a potent toxin […]<\/p>\n","protected":false},"author":843,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[4821],"tags":[],"class_list":["post-688607","post","type-post","status-publish","format-standard","hentry","category-news"],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p9NivD-2T8z","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/688607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/users\/843"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/comments?post=688607"}],"version-history":[{"count":0,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/posts\/688607\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/media?parent=688607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/categories?post=688607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.com\/index\/wp-json\/wp\/v2\/tags?post=688607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}